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Abstract
Background
Brain metastasis is a common endpoint in patients suffering from malignant melanoma.
However, little is known about factors that predispose to brain metastases.
Objective
We performed a retrospective clinical and pathological investigation of melanoma patients
with brain metastases in order to better characterise this patient population.
Methods
193 melanoma patients with brain metastasis histologically diagnosed between 1990 and
2015 at the University Hospital Zurich were retrospectively identified and further specified for
sex, age at diagnosis and detection of brain metastasis, and localisation. In addition, data
were extracted regarding the subtype of primary melanoma, Breslow tumour thickness, Clark
Level, mutation status, extent of metastatic spread and history of a secondmelanoma.
Results
We found a significant male predominance (n = 126/193; 65%; p < 0.001). Breslow tumour
thickness showed a wide range from 0.2 to 12.0 mm (n = 99; median 2.3 mm). 14 of 101
melanomas (14%) were classified as T1, thereof 11 (79%) were found in men. In 32 of 193
patients (17%), the primary melanoma was unknown.
Conclusions
Of special interest in our series is the high incidence of male predominance (79%) in cases
of thin metastasing melanoma (14%), implicating genetic or epigenetic (hormonal) gender
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differences underlying tumour progression. Additionally, the high percentage of unknown
primary melanoma (17%), at least partly representing completely regressed melanomas,
indicates the importance of immune surveillance in melanoma progression.
Introduction
The development of brain metastases, reported to occur in up to 25% of patients with cancer, is
a common and devastating complication of many systemic malignancies [1]. Cutaneous mela-
noma is a highly aggressive cancer with a propensity for brain metastases. The reported inci-
dence of cerebral metastases is variable and dependent on whether the source is clinical or
autopsy data, the patient population, and other factors. A study analysing 700 melanoma
patients treated at Roswell Park Memorial Institute from 1972 to 1978 found that 125/700
(18%) developed brain metastases [2]. In contrast, an autopsy study reported melanoma as the
most commonly encountered source of brain metastasis. The incidence of melanoma brain
metastasis was recorded as 91%, followed by breast (37%) and lung (34%) cancer [3]. An
important event during brain metastasis, at least for some cancers, is the extravasation of can-
cer cells from the vascular lumina across the blood-brain barrier, which consists of the vascular
endothelium and surrounding cells, into the brain parenchyma [4]. Not all cancers seem to
share the same propensity to cross the blood-brain barrier. Of note, microRNA-containing ves-
icles capable of destroying the blood-brain barrier have recently been identified as a mecha-
nism in breast cancer [5].
With particular reference to melanoma, the biology and mechanisms of brain metastasis
have received little attention in the literature. Recently, in vitro and in vivo studies by Lugassy
and Barnhill demonstrated the capacity of melanoma cells to spread to local and regional (and
perhaps even distant) sites via migration along the external (abluminal) surfaces of vascular
channels without intravasation [6]. This revolutionary new paradigm of tumour spread has
been termed extravascular migratory metastasis and may partially explain why brain metasta-
ses are so frequently encountered in melanoma.
In order to better understand the characteristics of this patient population, we retrospectively
analysed 193 patients with melanoma brain metastases, diagnosed between 1990 and 2015.
Patients and Methods
Study population
Patients were admitted at the University Hospital Zurich and some provided written informed
consent in accordance with the Declaration of Helsinki. As not all patients were able to do so,
Ethics Commission Zurich, Switzerland, also approved the here reported melanoma study
(approval number KEK-ZH-Nr. 2014–0193 and Stv. 16–2007, amendment 2014).
The electronic database of the Department of Pathology at the University Hospital Zurich,
existing since 1990, was searched for melanoma patients with histologically confirmed brain
metastasis between 1990 and 2015. In the clinical electronic database, which dates to 1995,
patients with histologically confirmed melanoma brain metastasis were further investigated for
sex, age at diagnosis of primary melanoma, the sequence and extent of metastatic spread.
In addition, we were interested in identifying patients without lymphatic spread, indicating
primary hematogenous or extravascular migratory dissemination. The primary melanoma was
characterised according to anatomic location, subtype, Breslow tumour thickness and Clark
Level. Brain metastases were further classified as either solitary or multiple. Since 2009 every
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initial melanoma metastasis was tested for the BRAFmutation status, followed by the NRAS
mutation analysis in BRAF wild-type tumours
Follow-up data were extracted, including the time interval between primary diagnosis and
manifestation of brain metastases and survival time. Survival information was collected in col-
laboration with the Cancer Registry Zurich and Zug, Switzerland.
Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics, version 21.0 (Armonk, NY: IBM
Corp.). Results of the descriptive statistics were expressed as numbers, percentages and median
with range. Data were analysed using the binominal test, chi-square test, Mann-Whitney U test
and the Kruskal-Wallis test. Overall survival was analysed using Kaplan-Meier curves. Median
survival is reported with 95% confidence intervals (CI). Groups were compared using the log-
rank test. All statistical tests were two-sided and an exact p-value< 0.05 was considered to be
statistically significant.
Results
Patients
193 patients with melanoma brain metastasis were identified. In this population, there was a
significant male predominance (126/193 men (65%) versus 67/193 women (35%); p< 0.001).
The median age at diagnosis of primary melanoma was 53.0 years (n = 149; range 15–82 years)
(Fig 1A). There was no significant age difference between men and women. The median age at
detection of brain metastasis was 60.0 years (n = 193; range 10–88 years) (Fig 1B). There was
no significant age difference between men and women.
Fig 1. Age distribution. (a) Black: age at diagnosis of primary melanoma (n = 149). (b) Grey: age at detection of brain metastasis (n = 193).
doi:10.1371/journal.pone.0156115.g001
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155 patients could be analysed with respect to the clinical time course. In the majority of patients
(n = 108/155; 70%), brain metastasis was detected later than metastasis to other organs. In 34
patients (22%) brain metastases were simultaneous (within 2 months) with metastases to other
organs. Eight patients (5%) presented with brain metastasis before metastasis to other organs. 5
patients (3%) harboured only brain metastasis. At the initial diagnosis of brain metastases, 98 of 193
patients (51%) presented with a solitary and 95 of 193 patients (49%) with multiple brain tumours.
15 of 193 patients (8%) had a history of a second primary melanoma.
Primary melanoma
The back was the most frequent location in males (26 of 90 melanomas; 29%) and the lower
extremities in females (14 of 49 melanomas; 29%). Males tended to have melanomas located on
the chest and abdomen (p = 0.06), whereas location on the arms was observed more frequently
in females (p = 0.07). Mucosal melanomas were significantly more common in women
(p = 0.02), taking into account that vaginal primary melanoma accounted for 2 of 5 mucosal
locations (40%) in women (Table 1).
Nodular melanoma (NM) was the most common subtype (44 of 105; 42%), followed by
superficial spreading melanoma (SSM) in 30 of 105 (29%). There was no significant gender dif-
ference in these two subtypes (Table 2).
Table 1. Location of the primary melanoma according to gender.
Total cases Male Female p-value
n = 139 n = 90 n = 49 (male vs female)
(100%) (100%) (100%)
Back 35 (25%) 26 (29%) 9 (18%) n.s.
Legs 28 (20%) 14 (16%) 14 (29%) n.s.
Head and neck 26 (19%) 20 (22%) 6 (12%) n.s.
Chest and abdomen 23 (17%) 19 (21%) 4 (8%) 0.06
Arms 20 (14%) 9 (10%) 11 (22%) 0.07
Mucosa 6 (4%) 1 (1%) 5 (10%) 0.02
Iris 1 (1%) 1 (1%) 0 (0%) n.s.
n.s., not signiﬁcant.
doi:10.1371/journal.pone.0156115.t001
Table 2. Subtypes of primarymelanoma according to gender.
Total cases Male Female p-value
n = 105 n = 72 n = 33 (male vs female)
(100%) (100%) (100%)
NM 44 (42%) 33 (46%) 11 (33%) n.s.
SSM 30 (29%) 22 (31%) 8 (24%) n.s.
ALM 7 (7%) 3 (4%) 4 (12%) n.s.
LMM 7 (7%) 4 (6%) 3 (9%) n.s.
Mucosal 6 (6%) 1 (1%) 5 (15%) 0.01
Other variants 11 (11%) 9 (13%) 2 (6%) n.s.
NM, nodular melanoma; SSM, superﬁcial spreading melanoma; ALM, acral lentiginous melanoma; LMM, lentigo maligna melanoma; n.s., not signiﬁcant.
doi:10.1371/journal.pone.0156115.t002
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In 101 melanomas, the T classification of the AJCC/UICC staging system [7] was reported.
14 melanomas (14%) were classified as T1 ( 1.00 mm thickness), 30 (30%) as T2 (1.01–2.00
mm thickness), 32 (32%) as T3 (2.01–4.00 mm thickness) and 25 (25%) as T4 (> 4 mm thick-
ness). There is a significant gender difference with regard to the T stages (p = 0.02). Males
account for 11 out of 14 (79%) T1 melanomas, 14 out of 30 (47%) T2 melanomas, 26 out of 32
(81%) T3 melanomas and 18 out of 25 (72%) T4 melanomas (Fig 2).
Breslow tumour thickness was reported in 99 primary melanomas and had median of 2.3
mm and a range of 0.2 to 12.0 mm. There was no significant difference in Breslow tumour
thickness between men and women (Fig 3). Median tumour thickness was 2.6 mm in men
(n = 67; range 0.2–12.0 mm) and 1.8 mm in women (n = 32; range 0.3–10.0 mm). Clark level
Fig 2. Comparison of T stages betweenmales and females.
doi:10.1371/journal.pone.0156115.g002
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was reported in 94 melanomas: 3 melanomas (3%) were classified as Clark Level II, 23 (25%) as
Clark Level III, 60 (64%) as Clark Level IV and 8 (9%) as Clark Level V.
Thirty-two of 193 (17%) patients had an unknown primary melanoma, 20 (63%) thereof
were males.
Mutation status
The mutation status was known in 55 of 193 (28%) patients. In 22 (40%) patients melanomas
were BRAF wild-type, 23 (42%) showed a BRAFmutation, and 10 (18%) a NRASmutation.
There was a significant difference in the age at detection of brain metastasis according to the
mutational status (p = 0.01). The median age at detection of brain metastasis was 56.0 years in
BRAFmutated tumours (range 35–71 years), 59.5 years in NRASmutated tumours (range 35–
76 years) and 69.5 years in BRAF wild-type tumours (range 40–75 years).
Comparing patients with and without lymph node metastasis
Information about lymph node involvement was available in 126 patients. In this cohort,
108 (86%) patients showed lymph node metastasis at the time when brain metastasis was
Fig 3. Comparison of Breslow tumour thickness betweenmales and females.
doi:10.1371/journal.pone.0156115.g003
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diagnosed, whereas 18 (14%) did not. Among 58 patients with positive nodes, 24 patients
(41%) were classified as N1, while the N2 and N3 stages contained 17 patients each (29%).
Metastases, apart from lymph nodes and brain, involved the skin, lung, liver, kidney, bone, and
other sites in 124 of 193 patients (64%) in the course of their disease.
We found a significant difference in melanoma subtype between patients with and without lymph
node metastasis (p = 0.006). All 26 patients with SSMmanifested lymphatic spread concurrent with
the diagnosis of brain metastasis. In contrast, the absence of lymph node metastasis was found in 3
out of 4 lentigo maligna melanomas (LMM) and in 10 out of 42 NM (24%). NM accounted for the
largest group of lymph node negative patients (10/16; 63%) (Table 3). There was no significant differ-
ence between patients with and without lymph nodemetastasis with respect to Breslow tumour
thickness. However, there was a significant difference in Breslow tumour thickness betweenmalig-
nant melanoma of NM and SSM types (p< 0.001). Breslow tumour thickness ranged from 1.4 to 9.0
mm in NM (n = 39; median 3.6 mm) and from 0.2 to 4.9 mm in SSM (n = 27; median 1.5 mm).
History of a second melanoma was significantly associated with the absence of lymph node
metastasis (p = 0.003).
We found no significant difference between patients with and without lymph node metasta-
sis with respect to sex, age at detection of primary melanoma or brain metastasis, occurrence of
metastases apart from the lymph nodes and the brain, number of brain metastases, Clark Level
and mutation status.
We found no significant difference in the location of primary melanoma with respect to age
at detection of brain metastasis.
Comparing cases with known and unknown primary melanoma
There was no significant difference between patients with known and unknown primary mela-
noma regarding sex, age at detection of brain metastasis, presence or absence of lymph node
metastasis, occurrence of metastases apart from the lymph nodes and the brain, number of
brain metastases and mutation status.
Compared to other primary melanomas, lymph node and visceral (other than brain) metas-
tases associated with unknown primary melanomas showed a significantly different clinical
time course (p = 0.04). In unknown primary melanomas, they were more commonly synchro-
nous (within 2 months) with brain metastases (9/19 cases; 47%). In contrast, most known pri-
mary melanomas (99/136; 73%) manifested the sequential development of lymph node or
Table 3. Subtypes of primary melanoma according to the presence or absence of lymph node
metastasis.
Total cases N+ N- p-value
n = 90 n = 74 n = 16 (N+ vs N-)
NM 42 (100%) 32 (76%) 10 (24%) n.s.
SSM 26 (100%) 26 (100%) 0 (0%) 0.004
ALM 6 (100%) 6 (100%) 0 (0%) n.s.
LMM 4 (100%) 1 (25%) 3 (75%) 0.02
Mucosal 3 (100%) 2 (67%) 1 (33%) n.s.
Other variants 9 (100%) 7 (78%) 2 (22%) n.s.
NM, nodular melanoma; SSM, superﬁcial spreading melanoma; ALM, acral lentiginous melanoma; LMM,
lentigo maligna melanoma; N+, lymph node positive melanoma; N-, lymph node negative melanoma; n.s.,
not signiﬁcant.
doi:10.1371/journal.pone.0156115.t003
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visceral metastases, later followed by brain metastases as the final step in tumour progression
(for details consult S1 Dataset).
Follow-up data
Survival and follow-up data were considered as reliable only if patients were dead or reported
alive within one year before the end of data collection. 166/193 (86%) patients fulfilled these
criteria and were included in the statistical survival analysis. 17 of these 166 well documented
patients (10%) were still alive in 2015 or 2016. Of those, 2 patients had a melanoma of
unknown primary. In the group of patients with unreliable follow-up data, 21/27 (78%) carried
the diagnosis of brain metastases 10 years or longer ago. Considering the short median survival
after diagnosis of brain metastasis (0.5 years) in patients with reliable follow-up, it is probable
that most patients with poor follow-up data are also dead (for details consult S2 Dataset).
The median age at death was 61.2 years (n = 149; range 24–89 years). There was no signifi-
cant age difference between men and women. The median time between diagnosis of primary
melanoma and of brain metastasis was 3.4 years (n = 149; range 0–33.2 years) without a signifi-
cant difference between men and women. Breslow tumour thickness neither significantly influ-
enced this time interval. The median survival after detection of brain metastasis was 0.47 years
(95% CI 0.39 to 0.66 years) with a borderline significantly better prognosis for women (n = 56;
median survival 0.71 years; 95% CI 0.43 to 1.0 years) compared to men (n = 110; median sur-
vival 0.43 years; 95% CI 0.32 to 0.56 years; p = 0.05). Breslow tumour thickness did not influ-
ence survival after brain metastasis. For the 17 patients who are still alive, the median follow-
up after diagnosis of brain metastasis was 1.9 years, range 0.2–13.5 years.
Discussion
In this study of 193 melanoma patients with brain metastases, men (65%) were more frequently
affected than women (35%). Gender is widely accepted as an independent prognostic factor in
predicting outcome for patients with cutaneous melanoma [8–10]. The predominance of men
with brain metastases is congruent with a previous study showing increased risk in men for vis-
ceral metastases and a correspondingly higher mortality rate [10]. As men have additional
unfavourable primary melanoma characteristics such as increased tumour thickness, ulcera-
tion, axial location and older age [11], there is uncertainty as to whether this gender difference
is due to behavioural factors or an inherent biological difference. Negligence with respect to
health care is often suggested to explain this gender difference for thick melanomas, as we
observed in this study. Aside from nodal status, Breslow tumour thickness remains among the
most important prognostic indicators for melanoma. Additionally, tumour thickness has been
reported as the only prognostic confounder affecting gender survival differences in one study
[10]. Therefore, our finding of a significant gender difference with regard to T stages (p = 0.02)
is of considerable interest. Of special note is the high percentage (14 of 101; 14%) of T1 stage
melanomas with clear-cut male predominance (79% men). This observation is supported by
previous studies indicating that female survival advantage relates at least partially to biological
differences, either tumour or host related [10, 12–14]. Interestingly a recent study demon-
strated that sex differences in melanoma survival is not related to mitotic rate of the primary
tumour [15]. In our study men displayed a borderline significantly shorter median survival
after detection of brain metastasis compared to women (p = 0.05). This observation under-
scores a survival benefit in women. However, interpretation of survival data is limited by the
different treatment regimens in this study cohort. Vice versa, the prognostic value of the cur-
rent dataset is enhanced by the fact that all patients underwent surgery at least once for histo-
logic confirmation of brain metastasis.
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Thin T1 melanomas have an excellent prognosis; the range of melanoma associated deaths
reported in the literature however is substantial (1–8% at 10 years [7, 16–18]). In addition,
many studies regarding melanoma recurrence and survival are reported with end points of 5 to
10 years. Especially for thin melanomas, this period of surveillance is too short since approxi-
mately 10% of lesions show recurrence beyond 10 years [19]. Many large multicentre survival
studies have failed to make adjustments to differentiate between death from all causes and
death due to disease. In such cases, longer observation periods may result in falsely high results.
Accordingly, our results with the endpoint of brain metastases provide more robust survival
information. Importantly, our data illustrate that there is a significant male predominance for
thin melanomas with subsequent brain metastasis.
Interestingly, we found 17% of patients with unknown primary melanomas. This incidence
is much higher than previously reported (3.2% [20] and 0.9% [21], respectively). In routine
clinical practice, metastatic melanoma with unknown primary is considered to originate from
completely regressed primary melanomas. From our experience, especially in immune com-
promised patients after organ transplantation [22], we fully recognise the importance of
immune surveillance in preventing the development and progression of cancer [23]. Regres-
sion is common in melanoma, particularly in thin lesions with radial growth phase. Its inci-
dence across all melanoma tumour thicknesses amounts to 10–35% [24], and up to 58% in thin
melanomas (< 0.75 mm) [25]. Regression has the following histologically defined phases: An
early phase characterised by an area of tumour accompanied by tumour infiltrating lympho-
cytes (TILS) and associated with necrosis of tumour cells. In the intermediate phase, tumour
gradually replaced by granulation tissue and partly pigmented macrophages. In the late phase,
the histological picture is dominated by scar with partly pigmented macrophages. In the final
phase, melanoma cells are completely replaced by scar tissue, thus precluding the histological
diagnosis of melanoma [26]. Clark et al. have shown in 1989 that TILS are associated with
good prognosis and many authors have confirmed this observation since then [9, 24, 25]. On
the contrary, prognostic significance of regression, particularly in patients with thin melano-
mas, has been lately controversially debated. Some studies have found that the presence of
regression is a poor prognostic indicator [26–31], while others found that it has no effect or
even a benefit on the risk of recurrence or survival [32–35]. Possible limitation of some multi-
institutional and multinational studies might be methodical inconsistencies, for example not
performing slide reviews. Additionally, assessment of regression has high interobserver vari-
ability [25, 28, 36]. Interestingly several studies have shown that thin melanomas with extensive
late regression have higher risk for metastatic disease [26, 29–31]. Our results coincide with
these findings.
In our patients with unknown primaries, which at least partially represent completely
regressed melanomas, there was a significant difference in the pattern of metastatic spread
(p = 0.04). Compared to other primary melanomas, lymph node and visceral (other than
brain) metastases associated with unknown primary melanomas were more commonly syn-
chronous (within 2 months) with brain metastases (in 9/19 cases; 47%), indicating an aggres-
sive clinical course. In contrast, most known primary melanomas (99/136; 73%) manifested
the sequential development of lymph node or visceral metastases, later followed by brain
metastases as the final step in tumour progression. However, this difference might result from
a diagnostic bias because all patients included in the study had brain metastasis. Unfortunately,
a prospective approach to confirm our results is not feasible.
Absence of lymph node metastases was found in 16 out of 90 (18%) melanoma patients at
the time of initial diagnosis of brain metastasis. Interestingly, most of those patients had pri-
mary melanomas of nodular type (10/16; 63%) with Breslow tumour thickness between 1.7
and 5.0 mm. In contrast, all 26 patients with SSM type melanoma showed lymph node
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metastases, and their tumours were significantly thinner when compared to NM type melano-
mas (p< 0.001) (Table 3). These observations suggest that tumour thickness plays an impor-
tant role in primary hematogenous metastasis.
Furthermore, patients without lymphatic spread had significantly greater numbers of multi-
ple primary melanomas (p = 0.003), indicating a special genetic and/ or immunological status
in this subgroup.
Interestingly, a recent study identified more frequent BRAF or NRASmutations in brain
metastases compared to primaries and metastasis at other sites [37]. The NRASmutation was
reported as an independent prognostic factor in metastatic melanoma [38]. Furthermore, mel-
anomas harbouring NRAS or BRAFmutations were associated with a trend towards worse sur-
vival and a greater likelihood of brain metastases at the time of initial diagnosis [37]. In our
cohort the BRAF and NRASmutation status was documented in 55 of 193 patients (29%): 22
patients (40%) manifested BRAF wild-type, 23 (42%) BRAFmutations, and 10 (18%) NRAS
mutations. The latter results are congruent with those found in the literature [39]. Depending
upon the mutational status of the patient, there was a significant difference in patient age at the
time of detection of brain metastases (p = 0.01). The median age at detection of brain metasta-
sis was 56.0 years in BRAFmutated tumours, 59.5 years in NRASmutated tumours and 69.5
years in BRAF wild-type tumours. This age difference between patients with BRAF and NRAS
mutations is consistent with that reported in the literature [38, 40–41].
Conclusions
What emerges from this study is a clearer picture of factors associated with brain metastasis in
patients suffering from malignant melanoma. Accordingly, our results provide a framework for
the reliable stratification of metastatic potential, which in turn should facilitate rational clinical
planning and treatment.
Of special interest are the higher incidence of thin melanomas (14%) with male predomi-
nance (79%) and the higher incidence of unknown primaries (17%) (representing at least partly
completely regressed melanomas) with metastatic disease if compared with the literature.
These findings illustrate the importance of gender (genetic or epigenetic) and immune surveil-
lance in melanoma progression.
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